Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025
Depreciation & amortization declines year over year
Q4 FY2025 depreciation & amortization of $181K fell 1.6% year over year. Over 3 fiscal years it compounded at -11.4% a year.
Context
- Depreciation & amortization amounted to 1100.0% of revenue in FY2025, up 1097.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 704K USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +2.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 704K | +6.7% |
| FY2024 | 2024-12-31 | 660K | -33.2% |
| FY2023 | 2023-12-31 | 988K | -2.5% |
| FY2022 | 2022-12-31 | 1.01M | +58.1% |
| FY2021 | 2021-12-31 | 640.98K | — |
Depreciation & Amortization vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.7% is the 4th highest of 8, against a peer median of -3.9%.
- Depreciation & amortization amounts to 1100.0% of revenue for CNTB, versus a peer median of 185.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.7M USD | -8.9% | +8.8% | 6.7% | |
| LTM Mar 2026 | $3.64M USD | -3.9% | +6.3% | 364.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.71M USD | +9.6% | +30.9% | — |
| FY2025 | $704K USD | +6.7% | -11.4% | 1100.0% | |
IMAImageneBio Inc | LTM Mar 2026 | $616K USD | +72.1% | -24.1% | — |
| LTM Mar 2026 | €377.74K EUR | -20.5% | -12.3% | 1287.9% | |
| LTM Mar 2026 | $168K USD | -72.2% | -41.8% | 2.4% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K USD | — | — | — |
| LTM Mar 2026 | $16.88K USD | +36.5% | +20.6% | — | |
| Peer median (excluding CNTB) | — | -3.9% | +6.3% | 185.5% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (204.94M) | (116.12M) | (59.38M) | (15.63M) | (55.48M) |
| Depreciation & Amortization | 640.98K | 1.01M | 988K | 660K | 704K |
| Deferred Income Tax | 106.37M | 3.37M | 0 | 0 | 0 |
| Stock-Based Compensation | 1.41M | 1.01M | 3.26M | 6.73M | 3.73M |
| Change in Working Capital | 3.27M | 7.16M | 9.49M | (15.49M) | 580K |
| Accounts Receivables | (2.53K) | 3.37K | 1.04M | (789K) | 776K |
| Inventory | 2.53K | (3.37K) | 0 | 0 | 0 |
| Accounts Payables | 8.89M | 375.66K | (4.28M) | (1.87M) | 1.62M |
| Other Working Capital | (5.62M) | 6.78M | 12.72M | (12.83M) | (1.82M) |
| Other Non-Cash Items | 6.91K | (1.35M) | (2.28M) | 118K | (736K) |
| Operating Cash Flow | (85.57M) | (99.27M) | (47.93M) | (23.61M) | (51.21M) |
| Capital Expenditures | (7.46M) | (4.28M) | (294K) | (750K) | (434K) |
| Acquisitions (Net) | 47.74K | 79.16K | 2.94M | 0 | 0 |
| Purchases of Investments | (17.98M) | (113.7M) | (32.6M) | (15.45M) | (30.47M) |
| Sales of Investments | 20.1M | 34.54M | 105.19M | 12.63M | 39.95M |
| Other Investing Activities | (47.74K) | (79.16K) | (84K) | 123K | 775K |
| Investing Cash Flow | (5.34M) | (83.44M) | 75.16M | (3.45M) | 9.82M |
| Debt Repayment | (126K) | (222K) | (290K) | 0 | 0 |
| Common Stock Issued | 219.99M | 18K | 44K | 227K | 1.09M |
| Common Stock Repurchased | (566K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | 119K | 0 | 0 | 0 |
| Financing Cash Flow | 206.66M | (91.29K) | (246K) | 227K | 1.09M |
| Effect of Forex Changes | (6.34M) | 13.87M | 18K | (595K) | 408K |
| Net Change in Cash | 109.42M | (168.93M) | 27M | (27.43M) | (39.89M) |
| Free Cash Flow | (93.03M) | (103.55M) | (48.22M) | (24.36M) | (51.64M) |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.